Celltrion unveiled its strategic roadmap for innovative drug development, with plans to submit 13 Investigational New Drug (IND) applications by 2028

The company’s growth strategy focuses on next-generation ADCs and multispecific antibodies, aiming to develop groundbreaking new drug treatments

Celltrion highlighted its ADC candidates, CT-P70 and CT-P71, targeting NSCLC and bladder cancer, respectively, using the new low-toxicity payload PBX-7016

The company plans to develop dual-payload ADCs, which combine two distinct payloads to deliver a more potent cytotoxic response to cancer cells

Celltrion is also focusing on multispecific antibodies, including CT-P72, which selectively targets cancer cells with improved on-target off-tumor toxicity

By 2025, Celltrion aims to have a portfolio of 11 drugs and is accelerating the development of next-generation therapies, with plans to introduce new drug candidates every year